Form 8-K - Current report:
SEC Accession No. 0001420720-26-000012
Filing Date
2026-07-17
Accepted
2026-07-17 16:08:53
Documents
12
Period of Report
2026-07-17
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20260717x8k.htm   iXBRL 8-K 35171
  Complete submission text file 0001420720-26-000012.txt   155319

Data Files

Seq Description Document Type Size
2 EX-101.SCH ibio-20260717.xsd EX-101.SCH 3502
3 EX-101.DEF ibio-20260717_def.xml EX-101.DEF 2848
4 EX-101.LAB ibio-20260717_lab.xml EX-101.LAB 17254
5 EX-101.PRE ibio-20260717_pre.xml EX-101.PRE 11362
15 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20260717x8k_htm.xml XML 4853
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 261183821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)